Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.

Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.

Webinar presenter Jeffrey Gregg, MD, University of Nevada

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace

Partnerships to develop POC diagnostic tests

January 2015—Chembio Diagnostics announced it has entered into an exclusive agreement with Integrated BioTherapeutics, a biotechnology company focused on the discovery of novel vaccines and therapeutics for emerging infectious diseases. Under the terms of the agreement, Chembio will combine its patented Dual Path Platform technology with IBT’s proprietary Ebola reagents to develop POC diagnostic tests for Ebola and febrile illness. Chembio will have exclusive rights to any POC product developed through this agreement.

Expanded platforms for hemoglobin A1c test

January 2015—Beckman Coulter Diagnostics has launched its next-generation Hemoglobin A1c assay with improved performance across its chemistry systems. The assay has been standardized for use on all platforms of the company’s AU clinical chemistry systems for off-line sample preparation use and for online sample preparation use on the company’s UniCel DxC systems and is FDA 510(k) cleared for both analyzers.

Chemically modified Taq polymerase

January 2015—Empirical Bioscience, formerly known as Syzygy Biotech, has introduced FlashTaq Hot-Start Taq DNA Polymerase, a chemically modified Taq polymerase designed to reduce nonspecific amplification in PCR.

Medical equipment financing

January 2015—Cornerstone Medical and Technology Finance specializes in assisting small medical practice owners obtain capital. Cornerstone can customize financing programs for pathologists who would like to remodel, expand, or relocate their office or to purchase additional equipment.

Monoclonal antibody patent issued

January 2015—Biocare Medical has been awarded a U.S. patent for its anti-PAX8 mouse monoclonal antibody, clone [BC12]. The PAX8 antibody [BC12] is designed to target a restricted epitope and exhibits higher specificity and provides sharper staining than the PAX8 rabbit polyclonal antibody.

Emergency-use Ebola virus kit

January 2015—Qiagen will offer global distribution of the RealStar Ebolavirus RT-PCR Kit 1.0. The diagnostic kit, developed and manufactured by Altona Diagnostics, is a reverse transcription polymerase chain reaction test intended for the qualitative detection of RNA from all known strains of Ebola viruses. Qiagen will distribute the kit and Altona’s already CE-IVD marked test, the RealStar Filovirus RT-PCR Kit, which is for both Ebola and Marburg viruses and does not fall under the emergency use authorization.

Advanced Cell Diagnostics awarded NCI grant, 12/14

December 2014—Advanced Cell Diagnostics has been awarded a two-year, $1.4 million grant from the National Cancer Institute under its Small Business Innovation Research Grant phase two program. ACD and its academic partner, Cleveland Clinic, will use the grant to develop and validate a diagnostic test based on ACD’s proprietary RNAscope technology for discriminating various B-cell non-Hodgkin lymphomas from benign lymphoproliferative diseases.

Affymetrix, Ariosa Diagnostics sign supply agreement, 12/14

December 2014—Affymetrix and Ariosa Diagnostics announced the signing of a multiyear supply agreement covering Affymetrix arrays and instruments to be used as part of Ariosa’s Harmony Non-Invasive Prenatal Test. The partnership enables Ariosa to pursue the development of a Harmony test kit that will allow laboratories worldwide to adopt and perform this test.

Reagent kits, 12/14

December 2014—Illumina announced new reagent kits for the HiSeq X Ten and HiSeq 2500 sequencing systems. For HiSeq X Ten Systems, the HiSeq X HD v2 Reagent Kit adds flexibility to population-scale human whole-genome sequencing by supporting an expanded menu of library preparation options.

FDA clearance for hematology workcell solution, 12/14

December 2014—Beckman Coulter Diagnostics received FDA 510(k) clearance for its UniCel DxH v3.0 software, which supports automated connectivity of the UniCel DxH 800 and DxH Slidemaker Stainer Coulter Cellular Analysis Systems.

MARKETPLACE

TRENDING